[1]

Rozaliyani A, Setianingrum F, Azahra S, Abdullah A, Fatril AE, et al. 2021. Performance of LDBio Aspergillus WB and ICT antibody detection in chronic pulmonary aspergillosis. Journal of Fungi 7(4):311

doi: 10.3390/jof7040311
[2]

Houben RMGJ, Dodd PJ. 2016. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Medicine 13(10):e1002152

doi: 10.1371/journal.pmed.1002152
[3]

Hosseini M, Shakerimoghaddam A, Ghazalibina M, Khaledi A. 2020. Aspergillus coinfection among patients with pulmonary tuberculosis in Asia and African countries: a systematic review and meta-analysis of cross-sectional studies. Microbial Pathogenesis 141:104018

doi: 10.1016/j.micpath.2020.104018
[4]

Smith NL, Denning DW. 2011. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. The European Respiratory Journal 37(4):865−72

doi: 10.1183/09031936.00054810
[5]

Nguyen NTB, Le Ngoc H, Nguyen NV, Dinh LV, Nguyen HV, et al. 2021. Chronic pulmonary aspergillosis situation among post tuberculosis patients in Vietnam: an observational study. Journal of Fungi 7(7):532

doi: 10.3390/jof7070532
[6]

Lee MR, Huang HL, Chen LC, Yang HC, Ko JC, et al. 2020. Seroprevalence of Aspergillus IgG and disease prevalence of chronic pulmonary aspergillosis in a country with intermediate burden of tuberculosis: a prospective observational study. Clinical Microbiology and Infection 26(8):1091.e1−1091.e7

doi: 10.1016/j.cmi.2019.12.009
[7]

Ray A, Chowdhury M, Sachdev J, Sethi P, Meena VP, et al. 2022. Efficacy of LD Bio Aspergillus ICT lateral flow assay for serodiagnosis of chronic pulmonary aspergillosis. Journal of Fungi 8(4):400

doi: 10.3390/jof8040400
[8]

Neuböck MJ, Günther G, Barac A, Davidsen JR, Laursen CB, et al. 2024. Chronic pulmonary aspergillosis as a considerable complication in post-tuberculosis lung disease. Seminars in Respiratory and Critical Care Medicine 45(1):102−13

doi: 10.1055/s-0043-1776913
[9]

Akram W, Ejaz MB, Mallhi TH, Syed Sulaiman SAB, Khan AH. 2021. Clinical manifestations, associated risk factors and treatment outcomes of chronic pulmonary aspergillosis (CPA): Experiences from a tertiary care hospital in Lahore, Pakistan. PLoS ONE 16(11):e0259766

doi: 10.1371/journal.pone.0259766
[10]

Maitre T, Cottenet J, Godet C, Roussot A, Abdoul Carime N, et al. 2021. Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis. European Respiratory Journal 58(2):2003345

doi: 10.1183/13993003.03345-2020
[11]

Ocansey BK, Otoo B, Adjei A, Gbadamosi H, Kotey FCN, et al. 2022. Chronic pulmonary aspergillosis is common among patients with presumed tuberculosis relapse in Ghana. Medical Mycology 60(9):myac063

doi: 10.1093/mmy/myac063
[12]

Setianingrum F, Rozaliyani A, Syam R, Adawiyah R, Tugiran M, et al. 2020. Evaluation and comparison of automated and manual ELISA for diagnosis of chronic pulmonary aspergillosis (CPA) in Indonesia. Diagnostic Microbiology and Infectious Disease 98(3):115124

doi: 10.1016/j.diagmicrobio.2020.115124
[13]

Iqbal N, Irfan M, Mushtaq A, Jabeen K. 2020. Underlying conditions and clinical spectrum of chronic pulmonary aspergillosis (CPA): an experience from a tertiary care hospital in Karachi, Pakistan. Journal of Fungi 6(2):41

doi: 10.3390/jof6020041
[14]

Russo A, Tiseo G, Falcone M, Menichetti F. 2020. Pulmonary aspergillosis: an evolving challenge for diagnosis and treatment. Infectious Diseases and Therapy 9(3):511−24

doi: 10.1007/s40121-020-00315-4
[15]

Patel D, Popple S, Claydon A, Modha DE, Gaillard EA. 2020. Posaconazole therapy in children with cystic fibrosis and Aspergillus-related lung disease. Medical Mycology 58(1):11−21

doi: 10.1093/mmy/myz015
[16]

Tashiro M, Takazono T, Izumikawa K. 2024. Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, treatment, and unresolved challenges. Therapeutic Advances in Infectious Disease 11:1−35

doi: 10.1177/20499361241253751
[17]

Page ID, Richardson MD, Denning DW. 2016. Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA). Journal of Infection 72(2):240−49

doi: 10.1016/j.jinf.2015.11.003
[18]

Takazono T, Izumikawa K. 2018. Recent advances in diagnosing chronic pulmonary aspergillosis. Frontiers in Microbiology 9:1810

doi: 10.3389/fmicb.2018.01810
[19]

Li H, Rui Y, Zhou W, Liu L, He B, et al. 2019. Role of the Aspergillus-specific IgG and IgM test in the diagnosis and follow-up of chronic pulmonary aspergillosis. Frontiers in Microbiology 10:1438

doi: 10.3389/fmicb.2019.01438
[20]

Sehgal IS, Choudhary H, Dhooria S, Aggarwal AN, Garg M, et al. 2018. Diagnostic cut-off of Aspergillus fumigatus-specific IgG in the diagnosis of chronic pulmonary aspergillosis. Mycoses 61(10):770−76

doi: 10.1111/myc.12815
[21]

Shin B, Koh WJ, Jeong BH, Yoo H, Park HY, et al. 2014. Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis. Journal of Infection 68(5):494−99

doi: 10.1016/j.jinf.2014.01.005
[22]

Denning DW, Page ID, Chakaya J, Jabeen K, Jude CM, et al. 2018. Case definition of chronic pulmonary aspergillosis in resource-constrained settings. Emerging Infectious Diseases 24(8):e171312

doi: 10.3201/eid2408.171312